Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease

英夫利昔单抗 医学 内科学 胃肠病学 炎症性肠病 阿达木单抗 槽水位 外科 疾病 他克莫司 移植
作者
Benjamin Pariente,Guillaume Pineton de Chambrun,Roman Krzysiek,Marine Desroches,Gauthier Louis,Chiara De Cassan,Clotilde Baudry,Jean‐Marc Gornet,Pierre Desreumaux,Dominique Émilie,Jean–Frédéric Colombel,Matthieu Allez
出处
期刊:Inflammatory Bowel Diseases [Oxford University Press]
卷期号:18 (7): 1199-1206 被引量:112
标识
DOI:10.1002/ibd.21839
摘要

BACKGROUND: Infliximab is effective for the treatment of refractory inflammatory bowel disease (IBD). Nevertheless, up to 40% of patients lose response to infliximab over time. The aim was to assess the clinical value of measuring infliximab trough levels and antibodies to infliximab (ATI) concentrations in IBD patients who lost response to infliximab therapy. METHODS: We retrospectively studied records of IBD patients who lost response to infliximab therapy. We first assessed clinical responses of different therapeutic strategies that were applied when patients lost response to infliximab and then we looked at the correlation between clinical response and infliximab trough levels and ATI concentrations. RESULTS: Seventy-six IBD patients were included. 31/76 patients (41%) continued infliximab therapy without any modification, 39 patients (51%) had an intensification of infliximab therapy, five patients (7%) had switched to adalimumab therapy, and one patient (1%) underwent surgery. Clinical response was observed in 27 patients (69%) with an intensification of infliximab therapy. There was no significant difference in mean infliximab trough level at inclusion in patients who responded to intensification of infliximab therapy (3.3 ± 4.1 μg/mL) as compared with patients who did not respond (2.3 ± 2.2 μg/mL, P = 0.85). In all, 16/76 patients (22.4%) presented detectable ATI in the serum. Ten ATI-positive patients had an intensification of infliximab therapy and six (60%) demonstrated a clinical response. After intensification of infliximab therapy the ATI concentration decreased in five patients. CONCLUSIONS: In patients with IBD who lose response to infliximab, clinical improvement may occur upon intensification of infliximab therapy, irrespective of infliximab serum concentration or presence of ATI.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wanci的应助被北岭梅花香到骨采纳,获得10
刚刚
刚刚
十八发布了新的文献求助10
刚刚
taoshiren发布了新的文献求助10
刚刚
所所的应助被QAQSS采纳,获得10
刚刚
seeU发布了新的文献求助10
刚刚
1秒前
胡楠发布了新的文献求助10
1秒前
1秒前
2秒前
无期完成签到 ,获得积分10
2秒前
2秒前
小马甲的应助被111采纳,获得10
2秒前
丘比特的应助被111采纳,获得10
2秒前
2秒前
xzn发布了新的文献求助10
2秒前
molihuakai的应助被111采纳,获得10
3秒前
li关闭了li的文献求助
3秒前
无花果的应助被111采纳,获得10
3秒前
3秒前
情怀的应助被包容明辉采纳,获得10
3秒前
3秒前
伊登的应助被111采纳,获得10
3秒前
小蘑菇的应助被111采纳,获得10
3秒前
3秒前
yrd完成签到 ,获得积分20
3秒前
薄暮知秋发布了新的文献求助10
3秒前
zhizhizhi发布了新的文献求助10
4秒前
小蘑菇的应助被铜豫采纳,获得10
5秒前
5秒前
楠楠DAYTOY发布了新的文献求助10
5秒前
三三主我之命完成签到 ,获得积分10
5秒前
zzzz发布了新的文献求助10
5秒前
随随发布了新的文献求助30
5秒前
Yu发布了新的文献求助10
5秒前
tttt完成签到,获得积分10
6秒前
6秒前
GJ发布了新的文献求助10
6秒前
jiangfei完成签到,获得积分10
6秒前
杨坤发布了新的文献求助10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8169822
求助须知:如何正确求助?哪些是违规求助? 9562742
关于积分的说明 21767517
捐赠科研通 7761280
什么是DOI,文献DOI怎么找? 3430523
关于科研通互助平台的介绍 2554282
邀请新用户注册赠送积分活动 2475214